Methods of Treating a Spastic Disorder in a Subject Having Underlying Condition(s)
The invention provides methods for treating primary disorders of mood and affect, including depressive disorders, anxiety and sleep disorders and CNS disorders comprising the administration of a neurotoxin.
1 . A method of treating a spastic disorder in a subject, the method comprising administering an effective amount of a pharmaceutical composition comprising a botulinum toxin A and a pharmaceutically acceptable carrier, thereby treating the spastic disorder, wherein the subject also has delayed sleep phase disorder, advanced sleep phase disorder, or any combination thereof.
2 . The method of claim 1 , wherein the administering comprises at least two multifocal injections that are at least one selected from the group consisting of transcutaneous, percutaneous, subcutaneous, intraperitoneal, transdermal, intramuscular, and intraosseous.
3 . A method of treating a spastic disorder in a subject, the method comprising administering an effective amount of a pharmaceutical composition comprising a botulinum toxin and a pharmaceutically acceptable carrier, thereby treating the spastic disorder, wherein the subject also has delayed sleep phase disorder, advanced sleep phase disorder, dysthymia and atopic disease, generalized anxiety disorder, or any combination thereof.
4 . The method of claim 3 , wherein the botulinum toxin is a type A botulinum toxin.
5 . The method of claim 4 , wherein the botulinum toxin type A is from a Hall strain Clostridium botulinum.
6 . The method of claim 3 , wherein the botulinum toxin is a type B botulinum toxin.
7 . The method of claim 4 , wherein the administering comprises an injection.
8 . The method of claim 7 , wherein the administering comprises at least two injections.
9 . The method of claim 8 , wherein the administering comprises at least two multifocal injections.
10 . The method of claim 9 , wherein the at least two multifocal injections are at least one selected from the group consisting of transcutaneous, percutaneous, subcutaneous, intraperitoneal, transdermal, intramuscular, and intraosseous.
11 . The method of claim 10 , wherein from 1.25 units to 3,000 units of the botulinum toxin are injected.
12 . The method of claim 11 , wherein at least 100 units of the botulinum toxin are injected.
13 . The method of claim 5 , wherein the administering comprises an injection.
14 . The method of claim 13 , wherein the administering comprises at least two injections.
15 . The method of claim 14 , wherein the administering comprises at least two multifocal injections.
16 . The method of claim 15 , wherein the at least two multifocal injections are at least one selected from the group consisting of transcutaneous, percutaneous, subcutaneous, intraperitoneal, transdermal, intramuscular, and intraosseous.
17 . The method of claim 16 , wherein from 1.25 units to 3,000 units of the botulinum toxin are injected.
18 . The method of claim 17 , wherein at least 100 units of the botulinum toxin are injected.
19 . The method of claim 6 , wherein the administering comprises an injection.
20 . The method of claim 19 , wherein the administering comprises at least two injections.
21 . The method of claim 20 , wherein the administering comprises at least two multifocal injections.
22 . The method of claim 21 , wherein the at least two multifocal injections are at least one selected from the group consisting of transcutaneous, percutaneous, subcutaneous, intraperitoneal, transdermal, intramuscular, and intraosseous.
23 . The method of claim 22 , wherein from 1.25 units to 3,000 units of the botulinum toxin are injected.
24 . The method of claim 23 , wherein at least 100 units of the botulinum toxin are injected.
25 . The method of claim 1 , wherein the pharmaceutically acceptable carrier comprises at least one selected from the group consisting of: an excipient; a surface active agent; a dispersing agent; an inert diluent; a granulating agent; a disintegrating agent; a binding agent; a lubricating agent; a preservative; a physiologically degradable material; an aqueous vehicle; a solvent; an oily vehicle; a suspending agent; a wetting agent; an emulsifying agent; a demulcent; a buffer; a salt; a thickening agent; a filler; an antioxidant; a stabilizing agent; a pharmaceutically acceptable polymeric material; and a hydrophobic material.
26 . The method of claim 3 , wherein the pharmaceutically acceptable carrier comprises at least one selected from the group consisting of: an excipient; a surface active agent; a dispersing agent; an inert diluent; a granulating agent; a disintegrating agent; a binding agent; a lubricating agent; a preservative; a physiologically degradable material; an aqueous vehicle; a solvent; an oily vehicle; a suspending agent; a wetting agent; an emulsifying agent; a demulcent; a buffer; a salt; a thickening agent; a filler; an antioxidant; a stabilizing agent; a pharmaceutically acceptable polymeric material; and a hydrophobic material.
27 . The method of claim 4 , wherein the pharmaceutically acceptable carrier comprises at least one selected from the group consisting of: an excipient; a surface active agent; a dispersing agent; an inert diluent; a granulating agent; a disintegrating agent; a binding agent; a lubricating agent; a preservative; a physiologically degradable material; an aqueous vehicle; a solvent; an oily vehicle; a suspending agent; a wetting agent; an emulsifying agent; a demulcent; a buffer; a salt; a thickening agent; a filler; an antioxidant; a stabilizing agent; a pharmaceutically acceptable polymeric material; and a hydrophobic material.
28 . The method of claim 5 , wherein the pharmaceutically acceptable carrier comprises at least one selected from the group consisting of: an excipient; a surface active agent; a dispersing agent; an inert diluent; a granulating agent; a disintegrating agent; a binding agent; a lubricating agent; a preservative; a physiologically degradable material; an aqueous vehicle; a solvent; an oily vehicle; a suspending agent; a wetting agent; an emulsifying agent; a demulcent; a buffer; a salt; a thickening agent; a filler; an antioxidant; a stabilizing agent; a pharmaceutically acceptable polymeric material; and a hydrophobic material.
29 . The method of claim 6 , wherein the pharmaceutically acceptable carrier comprises at least one selected from the group consisting of: an excipient; a surface active agent; a dispersing agent; an inert diluent; a granulating agent; a disintegrating agent; a binding agent; a lubricating agent; a preservative; a physiologically degradable material; an aqueous vehicle; a solvent; an oily vehicle; a suspending agent; a wetting agent; an emulsifying agent; a demulcent; a buffer; a salt; a thickening agent; a filler; an antioxidant; a stabilizing agent; a pharmaceutically acceptable polymeric material; and a hydrophobic material.
30 . The method of claim 12 , wherein the pharmaceutically acceptable carrier comprises at least one selected from the group consisting of: an excipient; a surface active agent; a dispersing agent; an inert diluent; a granulating agent; a disintegrating agent; a binding agent; a lubricating agent; a preservative; a physiologically degradable material; an aqueous vehicle; a solvent; an oily vehicle; a suspending agent; a wetting agent; an emulsifying agent; a demulcent; a buffer; a salt; a thickening agent; a filler; an antioxidant; a stabilizing agent; a pharmaceutically acceptable polymeric material; and a hydrophobic material.